Skip to main content

Table 3 Changes in biomarker levels from baseline to 12-weeks on treatment

From: Effects of de-escalated bisphosphonate therapy on bone turnover biomarkers in breast cancer patients with bone metastases

  Difference all patients p-value Difference treatment group 1 Difference treatment group 2 p-value
N   23   10 13  
CTx ng/L Median (IQR) 83 (2, 155) <0.001 17 (−27, 83) 131 (79, 171) 0.034
BSAP IU/L Median (IQR) 1 (0, 4) 0.011 0 (−1, 1) 3 (2, 5) 0.010
TGF-β, ng/ml Median (IQR) 0.8 (−2.1, 4.9) 0.28 −0.1 (−2.1, 2.2) 2.4 (−0.0, 4.9) 0.41
Activin-A, pg/ml Median (IQR) 111 (28, 526) 0.001 96 (−29, 596) 122 (34, 256) 0.60
NTx 2nM BCE/mM creatine Median (IQR) 42 (−48, 168) 0.15 42 (−15, 179) 45 (−76, 108) 0.54
P1NP ng/ml Median (IQR) 5742 (−6694, 19129) 0.24 1376 (−6694, 8498) 16539 (−1266, 21993) 0.26
BSP ng/ml Median (IQR) 5.8 (−8.0, 9.5) 0.63 0.5 (−15.4, 6.4) 9.8 (0.8, 47.2) 0.14
FACT -BP Median (IQR) 0 (−4, 3) 0.99 1 (0, 4) −2 (−4, 1) 0.053
BPI Median (IQR) 0 (−3, 4) 0.94 2 (0, 7) −1 (−8, 1) 0.050